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Case Reportsand vena contracta of 0.6 cm (Figure 1, A). The aortic
annulus was measured at 24 mm. Preoperative computed
tomography showed an effective aortic valve annulus of
24 mm and a perimeter of 80 mm, the sinotubular size
was 35 mm, and the aortic bulge was described at 36
mm. Because of her high perioperative risk and small,
calcified femoral arteries, multidisciplinary team chose
transapical aortic valve implantation. Owing to its posi-
tioning and anchoring facilities within the aortic root,
the Engager valve (Medtronic, Inc, Minneapolis, Minn),
with a size of 26 mm was chosen for implantation. The
valve size was dependent on the annulus size, which was
determined using both transesophageal echocardiography
and computed tomography. Transapical access was
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e38 The Journal of Thoracic and Cardiovascular Surgpassing the native valve with the device, the arches were
released and placed in the coronary sinuses (Figure 1,
B). Therefore, valve embolization into the left ventricle
was almost impossible. By pulling the device slightly
toward the left ventricle, the valve was finally released
(Figure 1, C). The initial invasive measurement showed
a trace residual aortic insufficiency and a peak gradient
of 5 mm Hg. The mitral valve insufficiency immediately
decreased from grade II to III to grade I.
The patient experienced atrioventricular blockage
(grade III) and required pacemaker implantation but was
discharged on postoperative day 12.
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20-year odyssey. Arch Cardiovasc Dis. 2012;105:146-52.Direct aortic transcatheter aortic valve implantation for pure aortic
valve regurgitation after implantation of a left ventricular
assist deviceRene Krause, MD, Dietrich Metz, MD, and Hasan Bushnaq, MD, Halle, GermanyThe increasing use of continuous-flow left ventricular assist
devices (LVADs) for the purpose of destination therapy has
led to associated secondary aortic valve insufficiency (AI)
as a significant complication.1,2 Significant AI can lead to
ineffective LVAD output and end-organ malperfusion,
with consequent symptoms of congestive heart failure and
significantly worse survival.3 The management of this
condition is challenging.
CLINICAL SUMMARY
A 65-year-old woman with an LVAD was readmitted to
our heart center because of recently increased shortness of
breath at rest. The patient’s medical history included
ischemic cardiomyopathy, chronic obstructive pulmonary
disease, pulmonary hypertension, moderate impaired renal
function, and type II diabetes mellitus. Because of theend-stage ischemic cardiomyopathy with terminal heart
failure (New York Heart Association class IV), she had un-
dergone an LVAD implantation (HeartMate II; Thoratec
Corporation, Pleasanton, Calif) from the left ventricular
apex to the ascending aorta through a sternotomy in
December 2009 (Figure 1).
Thereafter the patient recovered to a good general status.
During the routine follow-ups in 2012, she reported
increasing shortness of breath at daily activities. Echocardi-
ography showed at this time a new finding of AI of grade II.
Despite optimal medical therapy and LVAD adjustments,
her symptoms remained. The repeated echocardiography
after emergency admission showed moderate AI with vol-
ume overload of the left side of the heart as a result of a
continuous AI during systole and diastole (Figure 2). The
cusps and the annulus showed a mild degeneration as well
as an altered coapting function. LVAD function was
completely accurate. During hospitalization with optimal
medical treatment, the patient’s condition gradually deteri-
orated. She was therefore submitted for surgical treatment
of the AI.
Because of the patient’s poor general status, the multi-
morbidity and conducted heart surgery, we decided to
attempt transcatheter aortic valve implantation (TAVI).
The direct aortic access was chosen because of our previous
good experiences with this procedure. In this case, it pro-
vided some advantages to the femoral access.ery c April 2014
FIGURE 1. Standard posteroanterior chest radiograph shows the left
ventricular assist device (HeartMate II) and an implantable cardioverter
defibrillator.
Case ReportsPreoperative chest computed tomography and transeso-
phageal echocardiography were performed. Both showed
absent valvular calcification and depicted the exact position
of the outflow cannula. The perimeter of the aortic annulus
was measured by computed tomography at 26 mm and byFIGURE 2. Color DopplerM-mode echocardiography of the aortic valve insuffi
left ventricle.
The Journal of Thoracic and Catransesophageal echocardiography at 27 mm. We therefore
used an oversizing of 20% for choosing prosthesis size.
The procedure was performed by the senior author (H.B.)
and our interdisciplinary TAVI team.We performed an upper
partial ministernotomywith a J sternal incision (Figure 3). A
31-mm Medtronic CoreValve (Medtronic Inc, Minneapolis,
Minn)was slowly deployedunder angiographic and echocar-
diographic guidance. After it was released in an accurate po-
sition, the CoreValve migrated toward left ventricular
outflow tract, resulting in a moderate periprosthetic AI. We
therefore successfully implanted a second 31-mm valve as
a valve-in-valve technique (Figure 4). The LVADparameters
were unchanged through the procedure, with stable hemody-
namic conditions. The extubationwas proceeded in the oper-
ating roomand the patientwas transferred to the regularward
on the first postoperative day.
At follow-up 3, 6, and 12months later, shewas living inde-
pendently at home in New York Heart Association class II.
Echocardiography showed the prosthesis in a stable
position without evidence of further AI.DISCUSSION
The feasibility of TAVI in patients with implanted
LVADs has previously been reported.4,5 To the best of our
knowledge, however, the direct aortic approach in this
condition has never been documented in the literature.
Additionally, until now there has been limited experience
of the use of TAVI for pure native aortic valve
regurgitation without aortic stenosis. Absent aortic valveciency in the parasternal long-axis view shows continuous blood flow to the
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FIGURE 3. Primary access was obtained through a ministernotomy. Asterisk indicates left ventricular assist device outflow cannula; hash mark indicates
5F sheath in the distal ascending aorta.
Case Reportscalcification may hamper the anchoring of the prosthesis,
resulting in malpositioning. A recently published registry
analysis demonstrates that there is an increased need for a
second valve in that condition.6 In this case, the patient
had an elongated ascending aorta with widened annulus
of 27 mm and absent calcification. In our experience, direct
aortic access was the favorable approach to that condition.FIGURE 4. Posteroanterior radiograph obtained by using a standard
C-bow shows the final result with 2 CoreValves, both 31 mm, implanted
as a valve-in-valve technique.
e40 The Journal of Thoracic and Cardiovascular SurgBecause of the elongation of the ascending aorta, the direct
aortic access ensured an optimal angle for valve deploy-
ment as well as excellent control of the catheter. Further-
more, it provided optimal management of possible
therapy conversion and complications as well as full hemo-
dynamic support by the LVAD. After deployment of the
31-mm CoreValve in an accurate position, it migrated to-
ward the left ventricular outflow tract with concomitant
moderate AI and the need for a second valve. We suppose
that in addition to the anatomy this may be addressed to
the blood flow to the inflow cannula as well as the deficient
output of the left ventricle. We would recommend
decreasing the LVAD speed during deployment when using
a self-expanding device. In addition, anatomic issues might
be improved with future valve generations with improved
fixation and anatomically oriented designs.
Because there are several approaches to manage pure
aortic valve regurgitation in patients with LVADs, one
must consider percutaneous transcatheter aortic valve
closure.7 Further data are needed to evaluate the advantages
of these procedures. Direct aortic TAVI remains a safe pro-
cedure, however, and can be a reasonable option even in
patients with LVADs who are deemed to be in an inoperable
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JACC Cardiovasc Interv. 2013;6:84-9.Potential myocardial regeneration with CorMatrix ECM: A
case report
Bobby Yanagawa, MD, PhD, Vivek Rao, MD, PhD, Terrence M. Yau, MD, MSc, and
Robert J. Cusimano, MD, Toronto, Ontario, CanadaVideo clip is available online.
Pericardial and polytetrafluoroethylene patches are
currently the most commonly used materials for intraven-
tricular repair but are limited by calcification and retraction.
The extracellular matrix (ECM) biomaterial CorMatrix
ECM (CorMatrix Cardiovascular, Inc, Roswell, Ga) is an
absorbable tissue scaffold synthesized from decellularized
porcine small intestinal submucosa that is rich in collagen,
glycosaminoglycans, and growth factors. Furthermore,
in experimental models of myocardial infarction and
ventricular repair, ECM patches have been shown to
stimulate infiltration of cells, including cardiomyocytes,
as well as ECM production.1,2
The epicardial application of CorMatrix ECM has been
demonstrated to decrease infarct size and scar formation
after myocardial infarction.3 We have previously studied
the operative safety of the use of CorMatrix ECM for
left ventricular aneurysm repair and ventricular septal
defect repairs, with no primary repair failures.4 Here we
report a case of ventricular false aneurysm repair withCorMatrix ECM, which resulted in improvement of ven-
tricular contractile activity at 1-year follow-up.CLINICAL SUMMARY
A75-year-old female patient underwent 3-vessel coronary
artery bypass grafting 9 years before the index visit, then 3
years before the index visit had an acute infarction with
ventricular rupture. She underwent sutureless repair of a
false aneurysm with Bioglue (CryoLife, Inc, Kennesaw,
Ga) closure of the lateral ventricular wall.
The patient reported chest pain and syncope. Angiog-
raphy revealed a superficial false aneurysm (54 3 24 mm)
superimposed on a deeper false aneurysm (72 3 49 mm;
Figure 1, A, and Video 1). Transthoracic echocardiography
demonstrated inferior and inferolateral hypokinesis of
the left ventricle (left ventricular ejection fraction
20%-40%), ventricular dilation (left ventricular end-
systolic diameter 39 mm and left ventricular end-diastolic
diameter 53 mm), mild mitral regurgitation, and large false
aneurysms.
The patient underwent CorMatrix ECM false aneurysm
repair with femoral cannulation through a left thoracotomy.
The false aneurysm was opened under deep hypothermic
circulatory arrest (28C). The communication between the
superficial and deep false aneurysm was approximately
203 20 mm, and the more recent false aneurysm was filled
with thrombus. The neck of the old false aneurysm extend-
ing from the base of the papillary muscles to the apex was
closedwithCorMatrix ECMwith running 4-0monofilament
suture. The superficial false aneurysm was then closed.
The patient was rewarmed and decannulated.
Immediate postoperative echocardiography demon-
strated inferolateral and anterolateral mid-to-apical akinesis
of the left ventricle (left ventricular ejection fraction
35%-45%, left ventricular end-systolic diameter 35 mm,
left ventricular end-diastolic diameter 42 mm; Figure 1, Brdiovascular Surgery c Volume 147, Number 4 e41
